Cohance Lifesciences' Q3 FY 2025-26 Quarterly Results
- 13 Feb 2026
Result Summary
- Cohance Lifesciences Ltd reported a 3.6% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 70.6%.
- Its expenses for the quarter were up by 3.7% QoQ and 137.1% YoY.
- The net profit decreased 56.3% QoQ and decreased 65.2% YoY.
- The earnings per share (EPS) of Cohance Lifesciences Ltd stood at 0.96 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 550.71 | 571.17 | 322.86 | -3.6% | 70.6% |
Total Expenses | 505.25 | 487.40 | 213.13 | 3.7% | 137.1% |
Profit Before Tax | 40.60 | 83.77 | 109.73 | -51.5% | -63.0% |
Tax | 11.58 | 17.38 | 26.44 | -33.4% | -56.2% |
Profit After Tax | 29.02 | 66.39 | 83.29 | -56.3% | -65.2% |
Earnings Per Share | 0.96 | 1.93 | 3.23 | -50.3% | -70.3% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Cohance Lifesciences Ltd is a company operating in the pharmaceutical industry, focusing on the development, manufacturing, and marketing of a wide range of pharmaceutical products. The company is known for its active pharmaceutical ingredients (APIs), formulations, and biopharmaceuticals. As of the data available up to October 2023, no specific recent major developments have been highlighted for Cohance Lifesciences Ltd. However, like many companies in the pharmaceutical sector, it may be engaged in ongoing research and development activities aimed at expanding its product portfolio and enhancing its market presence.
Revenue
In the third quarter of the fiscal year 2026 (Q3FY26), Cohance Lifesciences Ltd reported a total income of ₹550.71 crores. This reflects a quarter-over-quarter (QoQ) decrease of 3.6% compared to the ₹571.17 crores recorded in the second quarter of fiscal year 2026 (Q2FY26). However, when compared year-over-year (YoY) to the third quarter of fiscal year 2025 (Q3FY25), there was a significant increase of 70.6% from ₹322.86 crores. This substantial YoY growth in total income indicates an expansion in the company's revenue-generating activities over the past year.
Profitability
For the third quarter of fiscal year 2026, Cohance Lifesciences Ltd's profit before tax (PBT) was ₹40.60 crores, showing a sharp decline of 51.5% from ₹83.77 crores in the previous quarter (Q2FY26). Year-over-year, the PBT decreased by 63.0% from ₹109.73 crores in Q3FY25. The tax expense for Q3FY26 was ₹11.58 crores, down 33.4% QoQ and 56.2% YoY. Consequently, the profit after tax (PAT) for Q3FY26 was ₹29.02 crores, marking a substantial decrease of 56.3% QoQ from ₹66.39 crores and 65.2% YoY from ₹83.29 crores. Earnings per share (EPS) followed a similar declining trend, recorded at ₹0.96, down from ₹1.93 in Q2FY26 and ₹3.23 in Q3FY25.
Operating Metrics
The financial data for Cohance Lifesciences Ltd in Q3FY26 reveals total expenses amounting to ₹505.25 crores. This represents an increase of 3.7% from the ₹487.40 crores reported in Q2FY26. Year-over-year, total expenses have surged by 137.1% from ₹213.13 crores in Q3FY25. These figures demonstrate a significant rise in the company's expenditure over both the quarterly and annual periods. The broader increase in expenses, alongside changes in revenue, has influenced the overall profitability and financial performance metrics for the quarter.